Valuation: AstraZeneca PLC

Market Cap 267B 234B 218B 201B 376B 25,509B 383B 2,589B 1,013B 12,651B 1,002B 981B 43,709B P/E 2026 *
22x
P/E 2027 * 19.2x
Enterprise Value 287B 252B 235B 216B 404B 27,418B 411B 2,782B 1,089B 13,598B 1,077B 1,054B 46,980B EV / Sales 2026 *
4.53x
EV / Sales 2027 * 4.17x
Free-Float
96.63%
Yield 2026 *
1.93%
Yield 2027 * 2.05%
1 day+1.67%
Current month+85.92%
6 months+86.28%
Current year+87.62%
Current year 89.04
Extreme 89.04
174.44
1 year 72.9
Extreme 72.895
174.44
3 years 60.47
Extreme 60.47
174.44
5 years 52.65
Extreme 52.65
174.44
10 years 25.55
Extreme 25.55
174.44
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Compliance Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
+1.67%+1.85% - - 267B
+1.93%+3.85%+51.05%+166.24% 1,089B
+0.29%+6.43%+60.47%+52.87% 643B
+2.45%+2.77%+39.61%+74.48% 465B
+2.17%+10.22%+41.17%+36.56% 359B
+1.46%+3.87%+39.70%+44.49% 303B
+2.73%+3.50%-25.66%-36.53% 226B
+4.48%+7.33%+30.47%+66.31% 212B
+2.91%+3.10%+18.84%+74.76% 167B
+2.35%+1.24%+3.87%-30.00% 144B
Average +2.29%+4.64%+28.84%+49.91% 400.89B
Weighted average by Cap. +2.05%+5.04%+39.93%+80.42%

Financials

2026 *2027 *
Net sales 63.3B 55.55B 51.73B 47.58B 89.19B 6,047B 90.72B 614B 240B 2,999B 238B 233B 10,362B 66.91B 58.72B 54.68B 50.29B 94.27B 6,392B 95.89B 649B 254B 3,170B 251B 246B 10,952B
Net income 12.08B 10.61B 9.88B 9.08B 17.03B 1,155B 17.32B 117B 45.86B 573B 45.37B 44.39B 1,978B 13.71B 12.03B 11.2B 10.31B 19.32B 1,310B 19.65B 133B 52.03B 650B 51.47B 50.36B 2,244B
Net Debt 19.98B 17.53B 16.33B 15.02B 28.15B 1,909B 28.63B 194B 75.82B 947B 75B 73.38B 3,270B 12.28B 10.77B 10.03B 9.23B 17.3B 1,173B 17.59B 119B 46.58B 582B 46.08B 45.09B 2,009B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
28/07/26 $172.48 +1.67% 4,740,936
27/07/26 $169.64 +0.22% 3,861,406
24/07/26 $169.26 +0.59% 2,009,993
23/07/26 $168.27 -0.86% 2,394,069
22/07/26 $169.73 +0.23% 1,683,823
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
172.15USD
Average target price
211.36USD
Spread / Average Target
+22.78%

Quarterly revenue - Rate of surprise